Lacnotuzumab is under clinical development by Novartis and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Lacnotuzumab’s likelihood of approval (LoA) and phase transition for Triple-Negative Breast Cancer (TNBC) took place on 23 Jun 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Lacnotuzumab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Lacnotuzumab overview

Lacnotuzumab is under development for the treatment of triple negative breast cancer, melanoma, endometrial carcinoma, pancreatic cancer. It is administered through intravenous route. It is a humanized monoclonal antibody that binds to macrophage colony stimulating factor (M-CSF). The therapeutic candidate was also under development for the treatment of prostate cancer and bone metastases, pigmented villonodular synovitis, tenosynovial giant cell tumour (giant cell tumor of the tendon sheath).

Novartis overview

Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Quick View Lacnotuzumab LOA Data

Report Segments
  • Innovator
Drug Name
  • Lacnotuzumab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Musculoskeletal Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.